Start-up Companies

University of Melbourne research has led to the creation of many start-up companies. Some examples are included here.

A personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.
3D models from point cloud data for any application. Automatic generation of building models from point clouds in common and standard data formats, increasing the productivity of surveying and architecture industries by automating the 3D building model generation process.
Developing novel, synthetic innate immunomodulators for the prevention of respiratory infections, initially targeting asthma and COPD exacerbations caused by viral respiratory infections.
Cochlear Limited is the leading global expert in implantable hearing solutions providing a range of proven, life-changing hearing solutions trusted by hundreds of thousands of people around the globe.
A spin-out of the University of Melbourne, developing drugs to treat fibrosis.
The developer of a proprietary next generation head lice treatment, Xeglyze™, effective on all lifecycle stages of the organism in a single application.
An innovative provider of choice for application acceleration services and solutions enabling software applications requiring high computation capability to run across a number of networked computers and servers, delivering increased performance and efficiency in a cost effective way.
A pioneering "4th generation" content delivery network (CDN) provider offering enterprise-class content delivery, video encoding and streaming services on an unmatched global scale.
A company formed to deliver an optical OFDM technology solution to increase bandwidth and reduce costs for telecommunications networks.
A Melbourne Australia based company developing a novel diagnostic for the dental health sector, which is highly sensitive in detecting early-stage tooth decay.
A start-up company from the University of Melbourne that was established to develop a novel nasal spray product based on betahistine, a pharmaceutical widely used in tablet form for the treatment of Meniere’s Disease and Vestibular Vertigo.
Cogstate is a leading cognitive science company focused on optimizing the measurement of cognition to guide better decision-making. Cogstate commercializes rapid, reliable, sensitive and simple computerized cognitive tests for clinical trials, academic research, healthcare and brain injury.
Bionic Vision.png
Bionic Vision Technologies (BVT) is a privately held Australian company that develops visual prostheses to restore vision to the blind. The devices operate by electrically stimulating the remaining retinal cells in patients with retinal degeneration.
Hort-Eye provides growers actionable crop analytics and insights to help them make timely and best decision of resources (water, fertilisers, pesticide) management and eventually enhance quality and quantity of produce.
Bionomics is a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders such as anxiety, depression and Alzheimer's disease. In a strong growth phase with a world-class portfolio of promising drug candidates from early to advanced stages of clinical development, this portfolio is fed by highly productive drug discovery platforms which include MultiCore®, a proprietary chemistry capability.
Prana Biotechnology.png
Prana Biotechnology is developing first-in-class therapies to treat orphan neurodegenerative diseases. Prana’s lead candidate, PBT434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration.
Synchron is a neural interface technology company based in Palo Alto, California, developing minimally-invasive technology for safe and rapid implantation of miniaturized electronic medical devices with broadband capability. The products are designed to help diagnose and treat a range of neurological disorders including speech deficit, paralysis, epilepsy, movement disorders and depression.
Certa Therapeutics is a clinical stage biotechnology company developing innovative therapies for the treatment of fibrotic diseases. Certa’s initial focus is on the development of treatments for Chronic Kidney Disease (CKD), a progressive condition which can lead to kidney failure and ultimately the need for dialysis or kidney transplantation.
Hexima is a biotechnology company actively engaged in the research and development of plant-derived proteins and peptides for applications as human therapeutics. Its lead drug candidate, HXP124, is in phase I/IIa clinical trials for the treatment of fungal toenail infections (onychomycosis).
MOG Laboratories Pty Ltd (MOGLabs) is an offshoot of an experimental atom optics laboratory at the University of Melbourne (Australia) offering products which balance outstanding performance, superb features, high-quality design, excellent ergonomics and moderate cost
Strax Corp.png
Strax HR-pQCT with Artificial Intelligence aids diagnosis of bone decay and identification of imminent risk of fragility fracture (1-2 years). It enables targeted protective therapy with a technology partnership of high resolution CT & AI.
OccuRx is a biopharmaceutical company focused on innovative therapeutic strategies for ocular diseases associated with inflammation and fibrosis.
Southern Innovation.png
Southern Innovation develops, markets and licenses patented pulse processing technologies for the rapid, accurate detection and measurement of radiation. Southern Innovation’s multi-award winning SITORO® technology provides a quantum leap in the efficiency of radiation detectors, with wide application in areas such as airport baggage screening, oil exploration, mineral analysis and the early detection of cancer.